1. Home
  2. CYTH vs SONM Comparison

CYTH vs SONM Comparison

Compare CYTH & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • SONM
  • Stock Information
  • Founded
  • CYTH 1990
  • SONM 1999
  • Country
  • CYTH United States
  • SONM United States
  • Employees
  • CYTH N/A
  • SONM N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • SONM Telecommunications Equipment
  • Sector
  • CYTH Health Care
  • SONM Telecommunications
  • Exchange
  • CYTH Nasdaq
  • SONM Nasdaq
  • Market Cap
  • CYTH 20.4M
  • SONM 17.8M
  • IPO Year
  • CYTH N/A
  • SONM 2019
  • Fundamental
  • Price
  • CYTH $0.69
  • SONM $3.33
  • Analyst Decision
  • CYTH Buy
  • SONM
  • Analyst Count
  • CYTH 3
  • SONM 0
  • Target Price
  • CYTH $0.95
  • SONM N/A
  • AVG Volume (30 Days)
  • CYTH 21.2K
  • SONM 10.1K
  • Earning Date
  • CYTH 11-14-2024
  • SONM 11-13-2024
  • Dividend Yield
  • CYTH N/A
  • SONM N/A
  • EPS Growth
  • CYTH N/A
  • SONM N/A
  • EPS
  • CYTH N/A
  • SONM N/A
  • Revenue
  • CYTH $870,725.00
  • SONM $56,744,000.00
  • Revenue This Year
  • CYTH N/A
  • SONM N/A
  • Revenue Next Year
  • CYTH $24.49
  • SONM $107.78
  • P/E Ratio
  • CYTH N/A
  • SONM N/A
  • Revenue Growth
  • CYTH N/A
  • SONM N/A
  • 52 Week Low
  • CYTH $0.59
  • SONM $2.32
  • 52 Week High
  • CYTH $2.12
  • SONM $10.70
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 47.10
  • SONM 51.64
  • Support Level
  • CYTH $0.61
  • SONM $3.03
  • Resistance Level
  • CYTH $0.77
  • SONM $3.42
  • Average True Range (ATR)
  • CYTH 0.05
  • SONM 0.23
  • MACD
  • CYTH -0.00
  • SONM -0.03
  • Stochastic Oscillator
  • CYTH 55.63
  • SONM 48.53

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the United States, and to Bell, Rogers, and Telus Mobility in Canada. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: